nispomeben   Click here for help

GtoPdb Ligand ID: 13507

Compound class: Synthetic organic
Comment: The chemical structure for nispomeben was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a non-opioid analgesic. It appears that this is the INN for Novaremed's clinical lead NRD.E1/NRD135S.E1 [1]. The mode of action of NRD.E1 involves inhibition of Lyn kinase phosphorylation, and not interactions with widely exploited pain-related targets (opioid, serotonin, GABA, NMDA or cannabinoid receptors, sodium or calcium channels). The exact mechanism of action remains to be determined.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 78.79
Molecular weight 357.44
XLogP 1.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H](COC[C@H](CC1=CC=C(C=C1)O)NC(=O)CCC2=CC=CC=C2)O
Isomeric SMILES C[C@@H](COC[C@H](CC1=CC=C(C=C1)O)NC(=O)CCC2=CC=CC=C2)O
InChI InChI=1S/C21H27NO4/c1-16(23)14-26-15-19(13-18-7-10-20(24)11-8-18)22-21(25)12-9-17-5-3-2-4-6-17/h2-8,10-11,16,19,23-24H,9,12-15H2,1H3,(H,22,25)/t16-,19-/m0/s1
InChI Key CDKPAWCGPQDCGU-LPHOPBHVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
As NRD135S.E1 this compound is a clinical candidate for the treatment of painful diabetic peripheral neuropathy [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05480228 EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA Phase 2 Interventional Massachusetts General Hospital
NCT02345291 Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients Phase 2 Interventional Novaremed Ltd. 1